AVIR · Categories · Form 4
AVIR - SEC Form 4 insider transactions
Atea Pharmaceuticals Inc. (AVIR) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for AVIR
- Officer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Medical Officer Horga Maria Arantxa converted options into 51,283 shares and covered exercise/tax liability with 16,073 shares, increasing direct ownership by 58% to 96,086 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Commercial Officer Vavricka John converted options into 42,083 shares and covered exercise/tax liability with 11,570 shares, increasing direct ownership by 59% to 82,594 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Development Officer Hammond Janet Mj converted options into 58,050 shares and covered exercise/tax liability with 14,136 shares, increasing direct ownership by 52% to 127,665 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Officer Corcoran Andrea converted options into 54,866 shares and covered exercise/tax liability with 16,104 shares, increasing direct ownership by 5% to 763,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- President, CEO, and Chairman Sommadossi Jean-Pierre covered exercise/tax liability with 106,093 shares and exercised 572,983 shares at a strike of $0.65, increasing direct ownership by 155% to 767,830 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- EVP, Chief Accounting Officer Foster Wayne converted options into 41,333 shares and covered exercise/tax liability with 12,132 shares, increasing direct ownership by 58% to 79,329 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Berger Franklin M converted options into 29,600 shares, increasing direct ownership by 6% to 506,497 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Duncan Barbara Gayle converted options into 29,600 shares, increasing direct ownership by 89% to 62,750 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Murphy Polly A. converted options into 29,600 shares, increasing direct ownership by 52% to 86,045 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Polsky Bruce converted options into 29,600 shares, increasing direct ownership by 45% to 95,206 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Adams Jerome M. converted options into 29,600 shares, increasing direct ownership by 89% to 62,750 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Lucidi Bruno converted options into 29,600 shares, increasing direct ownership by 36% to 112,750 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Berman Howard4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Kirsch Arthur S4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Development Officer Hammond Janet Mj was granted 11,250 shares, covered exercise/tax liability with 14,134 shares and converted options into 46,800 shares, increasing direct ownership by 117% to 81,388 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Officer Corcoran Andrea covered exercise/tax liability with 16,102 shares, converted options into 44,367 shares and was granted 10,500 shares, increasing direct ownership by 6% to 717,307 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- President, CEO, and Chairman Sommadossi Jean-Pierre was granted 99,517 shares, covered exercise/tax liability with 88,601 shares and converted options into 173,467 shares, increasing direct ownership by 158% to 300,940 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Commercial Officer Vavricka John converted options into 33,333 shares, was granted 8,750 shares and covered exercise/tax liability with 11,517 shares, increasing direct ownership by 142% to 52,081 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- EVP, Chief Accounting Officer Foster Wayne converted options into 33,333 shares, was granted 8,000 shares and covered exercise/tax liability with 12,062 shares, increasing direct ownership by 140% to 50,128 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Chief Medical Officer Horga Maria Arantxa converted options into 41,533 shares, was granted 9,750 shares and covered exercise/tax liability with 16,071 shares, increasing direct ownership by 137% to 60,876 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Berger Franklin M sold $1,023,475 worth of shares (359,606 units at $2.85), decreasing direct ownership by 44% to 451,897 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- President, CEO, and Chairman Sommadossi Jean-Pierre sold $234,155 worth of shares (57,969 units at $4.04) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Duncan Barbara Gayle4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Berger Franklin M4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Adams Jerome M.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Lucidi Bruno4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Polsky Bruce sold $61,144 worth of shares (17,544 units at $3.49), decreasing direct ownership by 21% to 65,606 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Director Murphy Polly A.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Lucidi Bruno converted options into 33,150 shares, increasing direct ownership by 66% to 83,150 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Polsky Bruce converted options into 33,150 shares, increasing direct ownership by 66% to 83,150 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Duncan Barbara Gayle converted options into 33,150 shares (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Murphy Polly A. converted options into 33,150 shares, increasing direct ownership by 142% to 56,445 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Berger Franklin M converted options into 33,150 shares, increasing direct ownership by 4% to 811,503 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Director Adams Jerome M. converted options into 33,150 shares (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Sommadossi Jean-Pierre sold $4,024 worth of shares (1,006 units at $4.00) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Corcoran Andrea sold $60,915 worth of shares (15,843 units at $3.84) and converted options into 44,367 shares, increasing direct ownership by 4% to 670,208 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Sommadossi Jean-Pierre converted options into 173,467 shares and sold $218,819 worth of shares (56,910 units at $3.85) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Horga Maria Arantxa converted options into 41,534 shares and sold $60,963 worth of shares (15,870 units at $3.84) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Foster Wayne converted options into 33,334 shares and sold $47,904 worth of shares (12,477 units at $3.84) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Vavricka John converted options into 33,334 shares and sold $45,420 worth of shares (11,819 units at $3.84) (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- Hammond Janet Mj sold $53,913 worth of shares (14,029 units at $3.84) and converted options into 46,800 shares, increasing direct ownership by 1,265% to 35,362 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Murphy Polly A.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Berger Franklin M4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Polsky Bruce4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Lucidi Bruno4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Duncan Barbara Gayle4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Adams Jerome M.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Foster Wayne4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Horga Maria Arantxa4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Sommadossi Jean-Pierre4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Corcoran Andrea4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Hammond Janet Mj4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Vavricka John4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4: Berger Franklin M sold $214,685 worth of shares (41,666 units at $5.15), decreasing direct ownership by 5% to 778,353 units4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Duncan Barbara Gayle4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Berger Franklin M4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Adams Jerome M.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Murphy Polly A.4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SEC Form 4 filed by Lucidi Bruno4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)